循环肿瘤DNA改善接受伊沙佐米、来那度胺和地塞米松治疗的复发/难治性多发性骨髓瘤患者的预后预测
该多中心、前瞻性、观察性研究对261例统一接受伊沙佐米、来那度胺和地塞米松治疗的复发/难治性多发性骨髓瘤患者进行骨髓浆细胞和循环肿瘤DNA的靶向捕获测序,发现循环肿瘤DNA中6个基因的突变数量是强预后预测因子,并基于循环肿瘤DNA突变数、血浆DNA浓度和临床因素建立预后指数,将患者分为3个类别,2年无进展生存率分别为57.9%、28.6%和0%。
要点
- 循环肿瘤DNA中KRAS、TP53、DIS3、BRAF、NRAS和ATM突变与更差的无进展生存期相关。
- 循环肿瘤DNA中6个相关基因的突变数量是强预后预测因子,0、1和≥2个突变患者的2年无进展生存率分别为57.3%、22.7%和0%。
- 基于循环肿瘤DNA突变数、血浆DNA浓度和临床因素建立的预后指数将患者分为3类,2年无进展生存率分别为57.9%、28.6%和0%。
核心结论
- 循环肿瘤DNA突变数量优于骨髓浆细胞突变用于复发/难治性多发性骨髓瘤的预后预测。
- 循环肿瘤DNA中TP53和KRAS突变在治疗后频繁出现。
研究设计与样本
- 多中心、前瞻性、观察性研究,纳入261例统一接受伊沙佐米、来那度胺和地塞米松治疗的复发/难治性多发性骨髓瘤患者。
- 对骨髓浆细胞和循环肿瘤DNA进行靶向捕获测序。
- 对94例患者进行循环肿瘤DNA突变的连续分析。
主要发现
- 在骨髓浆细胞和循环肿瘤DNA中分别检测到24个和47个反复突变基因。
- 循环肿瘤DNA中KRAS、TP53、DIS3、BRAF、NRAS和ATM突变与更差的无进展生存期相关。
- 骨髓浆细胞中TP53和KRAS突变与较差的无进展生存期相关,而KRAS突变仅在骨髓浆细胞和循环肿瘤DNA同时检测到时具有预后相关性。
- 循环肿瘤DNA中6个相关基因的突变数量是强预后预测因子,0、1和≥2个突变患者的2年无进展生存率分别为57.3%、22.7%和0%。
- 基于循环肿瘤DNA突变数、血浆DNA浓度和临床因素建立的预后指数将患者分为3类,2年无进展生存率分别为57.9%、28.6%和0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It remains elusive how driver mutations, including those detected in circulating tumor DNA (ctDNA), affect prognosis in relapsed/refractory multiple myeloma (RRMM). Here, we performed targeted-capture sequencing using bone marrow plasma cells (BMPCs) and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, and dexamethasone in a multicenter, prospective, observational study. We detected 24 and 47 recurrently mutated genes in BMPC and ctDNA, respectively. In addition to clonal hematopoiesis-associated mutations, varying proportion of driver mutations, particularly TP53 mutations (59.2% of mutated cases), were present in only ctDNA, suggesting their subclonal origin. In univariable analyses, ctDNA mutations of KRAS, TP53, DIS3, BRAF, NRAS, and ATM were associated with worse progression-free survival (PFS). BMPC mutations of TP53 and KRAS were associated with inferior PFS, whereas KRAS mutations were prognostically relevant only when detected in both BMPC and ctDNA. A total number of ctDNA mutations in the 6 relevant genes was a strong prognostic predictor (2-year PFS rates: 57.3%, 22.7%, and 0% for 0, 1, and ≥2 mutations, respectively) and independent of clinical factors and plasma DNA concentration. Using the number of ctDNA mutations, plasma DNA concentration, and clinical factors, we developed a prognostic index, classifying patients into 3 categories with 2-year PFS rates of 57.9%, 28.6%, and 0%. Serial analysis of ctDNA mutations in 94 cases revealed that TP53 and KRAS mutations frequently emerge after therapy. Thus, we clarify the genetic characteristics and clonal architecture of ctDNA mutations and demonstrate their superiority over BMPC mutations for prognostic prediction in RRMM. This study is a part of the C16042 study, which is registered at www.clinicaltrials.gov as #NCT03433001.
引用
- Kogure Y, Handa H, Ito Y, et al. ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood. 2024. PMID: 38427753. doi:10.1182/blood.2023022540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。